Patents by Inventor Jesper Lau

Jesper Lau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8603972
    Abstract: The invention relates to protracted GLP-1 compounds and therapeutic uses thereof.
    Type: Grant
    Filed: March 20, 2006
    Date of Patent: December 10, 2013
    Assignee: Novo Nordisk A/S
    Inventors: Jesper Lau, Florencio Zaragoza Dorwald, Lauge Schaffer, Thomas Kruse Hansen
  • Patent number: 8586614
    Abstract: The invention provides a compound of general formula (I) wherein the substituents are defined further in the application, as well as further embodiments hereof described in the attached embodiments. The present invention also provides use of the compounds of the invention for preparation of a medicament for the treatment of various diseases, e.g. for the treatment of type 2 diabetes.
    Type: Grant
    Filed: December 7, 2010
    Date of Patent: November 19, 2013
    Assignee: Novo Nordisk A/S
    Inventors: Jesper Lau, Anthony Murray, Per Vedso, Marit Kristiansen, Lone Jeppesen
  • Publication number: 20130288960
    Abstract: The invention relates to a derivative of a GLP-1 analogue, which analogue comprises a first K residue at a position corresponding to position 18 of GLP-1 (7-37) (SEQ ID NO: 1), a second K residue at another position, and a maximum of twelve amino acid changes as compared to GLP-1 (7-37); which derivative comprises two protracting moieties attached to said first and second K residue, respectively, via a linker, wherein the protracting moiety is selected from Chem. 1, Chem. 2, and Chem. 3: Chem.: HOOC—(CH2)x—CO—* Chem. 2: HOOC—C6H4-0-(CH2)y—CO—* Chem. 3: R2—C6H4—(CH2)z—CO—*, in which x is an integer in the range of 6-18, y is an integer in the range of 3-17, z is an integer in the range of 1-5, and R2 is a group having a molar mass not higher than 150 Da; and the linker comprises Chem. 4: *—NH—(CH2)2-(0-(CH2)2)k-0-(CH2)n—CO—*. wherein k is an integer in the range of 1-5, and n is an integer in the range of 1-5; or a pharmaceutically acceptable salt, amide, or ester thereof.
    Type: Application
    Filed: November 9, 2011
    Publication date: October 31, 2013
    Applicant: Novo Nordisk A/S
    Inventors: Alice Ravn Madsen, Birgit Wieczorek, Jacob Kofoed, Jesper Lau, Jane Spetzler, Janos Tibor Kodra, Lars Linderoth, Patrick William Garibay, Per Sauerberg, Thomas Kruse
  • Publication number: 20130244931
    Abstract: Novel polypeptide derivatives having protracted profile of action.
    Type: Application
    Filed: May 28, 2013
    Publication date: September 19, 2013
    Inventors: Jesper Lau, Thomas Kruse Hansen, Kjeld Madsen, Paw Bloch, Florencio Zaragoza Dorwald, Niels Langeland Johansen
  • Publication number: 20130243770
    Abstract: The present invention describes a method of treating diabetes or metabolic syndrome with a compound that inhibits (a) IL-1, (b) the synthesis of IL-1, or (c) the release of IL-1.
    Type: Application
    Filed: May 22, 2013
    Publication date: September 19, 2013
    Applicant: Novo Nordisk A/S
    Inventor: Jesper Lau
  • Patent number: 8536122
    Abstract: Protracted GLP-1 compounds and therapeutic uses thereof.
    Type: Grant
    Filed: March 5, 2012
    Date of Patent: September 17, 2013
    Assignee: Novo Nordisk A/S
    Inventors: Jesper Lau, Florencio Zaragoza Doerwald, Paw Bloch, Thomas Kruse Hansen
  • Patent number: 8486890
    Abstract: The present invention relates to novel amylin derivatives having a protracted action profile, to pharmaceutical compositions comprising these derivatives and to the use of the derivatives for the treatment of diseases related to obesity, diabetes and other metabolic disorders.
    Type: Grant
    Filed: March 15, 2007
    Date of Patent: July 16, 2013
    Assignee: Novo Nordisk A/S
    Inventors: Thomas Kruse Hansen, Lauge Schäffer, Jesper Lau
  • Publication number: 20130059853
    Abstract: Novel biaryl compounds with phosphodiesterase inhibitory activity of the general formula (I), wherein R1, R2, R3, X, Y, Z1, Z2, Z3, and Z4 have the meanings defined herein, as well as their use as therapeutic agents in the treatment of inflammatory diseases and conditions.
    Type: Application
    Filed: April 28, 2011
    Publication date: March 7, 2013
    Applicant: LEO PHARMA A/S
    Inventors: Simon Feldbaek Nielsen, Anne Marie Horneman, Jesper Lau, Jens Christian Hojland Larsen
  • Publication number: 20130053315
    Abstract: Novel polypeptide derivatives having protracted profile of action.
    Type: Application
    Filed: March 22, 2012
    Publication date: February 28, 2013
    Inventors: Jesper Lau, Thomas Kruse Hansen, Kjeld Madsen, Paw Bloch, Florencio Zaragoza Dorwald, Nils Langeland Johansen
  • Publication number: 20130053311
    Abstract: The invention relates to a GLP-1 analogue which comprises a histidine (H) residue at a position corresponding to position 31 of GLP-1 (7-37) (SEQ ID NO: 1), a glutamine (Q) residue at a position corresponding to position 34 of GLP-1 (7-37) (SEQ ID NO: 1), and a maximum of ten amino acid modifications as compared to GLP-1 (7-37) (SEQ ID NO: 1); wherein the H residue is designated H31, and the Q residue is designated Q34; or a pharmaceutically acceptable salt, amide, or ester thereof. The invention also relates to derivatives thereof, as well as the pharmaceutical use of these analogues and derivatives, for example in the treatment and/or prevention of all forms of diabetes and related diseases. The invention furthermore relates to corresponding novel side chain intermediates. The derivatives are suitable for oral administration.
    Type: Application
    Filed: December 16, 2010
    Publication date: February 28, 2013
    Applicant: Novo Nordisk A/S
    Inventors: Christoph Kalthoff, Jesper Lau, Jane Spetzler, Patrick William Garibay, Jacob Kofoed, Lars Linderoth
  • Publication number: 20130040884
    Abstract: Novel polypeptide derivatives having protracted profile of action.
    Type: Application
    Filed: March 22, 2012
    Publication date: February 14, 2013
    Inventors: Jesper Lau, Thomas Kruse Hansen, Kjeld Madsen, Paw Bloch, Florencio Zaragoza Dorwald, Nils Langeland Johansen
  • Patent number: 8362049
    Abstract: This application relates to novel urea glucokinase activators and use of the compounds of the invention for preparation of a medicament for the treatment of various diseases, e.g. for the treatment of type 2 diabetes. Further encompassed is a pharmaceutical composition comprising a compound according to the invention and a process for preparing such.
    Type: Grant
    Filed: March 8, 2012
    Date of Patent: January 29, 2013
    Assignee: Novo Nordisk A/S
    Inventors: Anthony Murray, Jesper Lau, Per Vedsoe, Lise Brown Christiansen
  • Patent number: 8318778
    Abstract: This application relates to novel urea glucokinase activators and use of the compounds of the invention for preparation of a medicament for the treatment of various diseases, e.g. for the treatment of type 2 diabetes. Further encompassed is a pharmaceutical composition comprising a compound according to the invention and a process for preparing such.
    Type: Grant
    Filed: January 8, 2008
    Date of Patent: November 27, 2012
    Assignee: Novo Nordisk A/S
    Inventors: Anthony Murray, Jesper Lau, Per Vedsø, Lise Brown Christiansen
  • Publication number: 20120295847
    Abstract: Protracted GLP-1 compounds and therapeutic uses thereof.
    Type: Application
    Filed: March 5, 2012
    Publication date: November 22, 2012
    Applicant: Novo Nordisk A/S
    Inventors: Jesper Lau, Florencio Zaragoza Dörwald, Henrik Stephensen, Paw Bloch, Thomas Kruse Hansen, Kjeld Madsen
  • Publication number: 20120289453
    Abstract: Novel GLP-1 compounds and their therapeutic use.
    Type: Application
    Filed: May 16, 2012
    Publication date: November 15, 2012
    Applicant: Novo Nordisk A/S
    Inventors: Nils Langeland Johansen, Jesper Lau, Kjeld Madsen, Thomas Kruse Hansen, Jeppe Sturis
  • Publication number: 20120283170
    Abstract: This invention provides new therapeutic peptides, i.e. new protracted Exendin-4 compounds, pharmaceutical compositions and the use of such.
    Type: Application
    Filed: May 1, 2012
    Publication date: November 8, 2012
    Applicant: Novo Nordisk A/S
    Inventors: Jesper Lau, Thomas Kruse Hansen, Leif Christensen, Kjeld Madsen, Lauge Schaeffer, Jane Spetzler
  • Patent number: 8263634
    Abstract: This invention relates to compounds of formula (I) which are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.
    Type: Grant
    Filed: November 9, 2010
    Date of Patent: September 11, 2012
    Assignee: Novo Nordisk A/S
    Inventors: Anthony Murray, Jesper Lau, Lone Jeppesen, Per Vedsø, Michael Ankersen, Jane Marie Lundbeck, Marit Kristiansen, Maria Carmen Valcarce-Lopez, Dharma Rao Polisetti, Govindan Subramanian, Robert Carl Andrews, Daniel P. Christen, Jeremy T. Cooper, Kalpathy Chidambareswarak Santhosh
  • Patent number: 8211925
    Abstract: The present invention relates to N-heteroaryl-benzamides, pharmaceutical compositions comprising the same, and methods of using the same. The N-heteroaryl-benzamides are useful in diseases or medical conditions mediated by glucokinase.
    Type: Grant
    Filed: April 27, 2007
    Date of Patent: July 3, 2012
    Assignee: TransTech Pharma, Inc.
    Inventors: Anthony Murray, Jesper Lau, Lone Jeppsen, Per Vedsø, Dharma Rao Polisetti, Bapu Reddy Gaddam, Daniel P. Christen, Kalpathy Chidambareswaran Santhosh, Jeremy T. Cooper, Robert Carl Andrews
  • Patent number: 8148413
    Abstract: This invention relates to compounds that are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial. The compounds are of the general formula (I) wherein A and B are further defined in the application.
    Type: Grant
    Filed: September 30, 2010
    Date of Patent: April 3, 2012
    Assignee: TransTech Pharma, Inc.
    Inventors: Jesper Lau, Per Vedsø, János Tibor Kodra, Anthony Murray, Lone Jeppesen, Michael Ankersen, Govindan Subramanian, Adnan M. M. Mjalli, Robert Carl Andrews, Dharma Rao Polisetti, Daniel Peter Christen
  • Patent number: 8138185
    Abstract: This application relates to novel urea glucokinase activators and use of the compounds of the invention for preparation of a medicament for the treatment of various diseases, e.g. for the treatment of type 2 diabetes. Further encompassed is a pharmaceutical composition comprising a compound according to the invention and a process for preparing such.
    Type: Grant
    Filed: January 8, 2008
    Date of Patent: March 20, 2012
    Assignee: Novo Nordisk A/S
    Inventors: Anthony Murray, Jesper Lau, Per Vedsø